IQWiG finds no proven added benefit for adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma

IQWiG dossier assessment A25-155, published on 16 March 2026, concluded that added benefit of adjuvant cemiplimab is not proven in high-risk cutaneous squamous cell carcinoma because available C-POST follow-up is too short for robust recurrence-focused interpretation.